Work

MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer

Year: 2019

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.08.612

Authors: D.R. Camidge, F. Barlesi, J. Goldman, D. Morgensztern, R. Heist, E. Vokes, A. Spira, E. Angevin, W. Su, D. Hong, J. Strickler, M. Motwani, Z. Sun, A. Parikh, P. Komarnitsky, J. Wu, K. Kelly

Institutions: University of Colorado Cancer Center, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, University of California, Los Angeles, Washington University in St. Louis, Massachusetts General Hospital, University of Chicago, Virginia Cancer Specialists, Institut Gustave Roussy, Fondation Gustave Roussy, National Cheng Kung University Hospital, The University of Texas MD Anderson Cancer Center, Duke Medical Center, AbbVie (United States), UC Davis Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2982250093

Cites:

Cited by: 2

Related to: 10